CVS Health received positive news when Medicare finalized a 2.5% payment increase to providers, significantly better than the initially proposed 0.09% increase. This $13 billion boost to insurers like CVS's Aetna unit improves profitability outlook. Trading at 11x forward earnings compared to peers at 15-20x, CVS appears undervalued with potential to reach $90-$100 per share, supported by 3.4% dividend yield and expected earnings growth.

CVS Health received positive news that should help boost revenue and profitability for the healthcare company. The developments were well-received by the healthcare industry, though specific details of the news are not provided in the article excerpt.

The article recommends CVS Health and Bristol Myers Squibb as recession-resistant dividend stocks worth buying at current valuations. Both companies have maintained their dividends through economic downturns over the past 20 years and operate in healthcare sectors that perform well during recessions. CVS trades at 10.3x forward earnings with a 3.37% dividend yield, while Bristol Myers trades at 9.5x forward earnings with a 4.20% dividend yield.

CVS Health stock is being weighed down by regulatory headwinds, but the company has received positive news that could make it more attractive as a dividend stock. The article examines whether CVS represents an undervalued investment opportunity despite current challenges.

The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing greater rate predictability for insurers. Major healthcare stocks surged on the positive announcement.

A $100 investment in CVS Health five years ago would be worth $108.11 today, representing only 1.6% annual growth. This significantly underperforms the S&P 500, which would have grown to $171.46 (11% annually). CVS faces headwinds including pressure on profit margins from rising costs and limited rate increases for its Medicare Advantage plans, though it offers a solid 3.62% dividend yield.

NATPAT, a plant-based wellness brand, announced the launch of its BuzzPatch mosquito repellent and MagicPatch itch relief patches at over 4,700 CVS Pharmacy locations across 48 states starting March 20, 2026. The DEET-free patches offer chemical-free alternatives to conventional sprays and creams, marking the company's largest brick-and-mortar retail expansion to date.

Following recent market pullbacks, two healthcare stocks stand out as recovery opportunities: CVS Health, which faces Medicare Advantage reimbursement pressures but benefits from its diversified business model, and AbbVie, whose strong-performing immunology drugs Skyrizi and Rinvoq are offsetting Humira's patent-driven decline while maintaining a 54-year dividend increase streak.

Bioliberty, a healthtech startup, announced a $10.2 million Series A funding round led by the Scottish National Investment Bank ($4M) to expand its Lifehub Clinic platform with computer vision and care coordination capabilities. The company also launched Lifehub Home for at-home therapy tracking. Russell Bailey from Lifepoint Health and Dana Prommel Strauss from CVS Health joined the board, bringing healthcare expertise to support U.S. commercialization.

CVS Health announced that its board of directors approved a quarterly dividend of $0.665 per share on common stock, payable on May 4, 2026, to shareholders of record on April 23, 2026.

Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.

Glenview Capital Management initiated a new $96.45 million position in DigitalOcean Holdings during Q4 2025, acquiring 2,004,299 shares. The investment became the fund's 11th-largest holding at 1.96% of AUM. DigitalOcean reported strong earnings with 18% revenue growth, 123% spike in ARR from $1M+ customers, and 150% AI ARR growth, positioning itself as a platform for high-growth cloud and AI workloads.